Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy — PISCES

Locally Advanced or Metastatic NSCLC Clinical Trial

Official title:
Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in EGFR Mutation-Positive, Locally Advanced or Metastatic Chinese NSCLC Patients, Who Have Progressed From First-line EGFR-TKI Therapy (PISCES)

Status Completed

Clinical Trial Summary

To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.

Clinical Trial Description

The objectives of this study are to assess molecular testing, treatment patterns, and associated clinical outcomes among patients with epidermal growth factor receptor (EGFR) mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed from first-line EGFR-TKI (tyrosine kinase inhibitor) therapy. This study is descriptive in nature and does not attempt to test any specific a priori hypotheses ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Locally Advanced or Metastatic NSCLC

Clinical Trial Details

NCT number	NCT04207775
Study type	Observational
Source	AstraZeneca
Contact
Status	Completed
Phase
Start date	March 30, 2020
Completion date	September 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03037086` - Asia PDL1 Study Among NSCLC Patients	N/A
Recruiting	`NCT05662670` - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03274479` - PBF-1129 in Patients With NSCLC	Phase 1
Recruiting	`NCT03502850` - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT05990127` - A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT03969823` - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC	N/A
Completed	`NCT05631678` - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole	Phase 1
Recruiting	`NCT04143607` - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC	Phase 3
Completed	`NCT03414814` - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation	Phase 2
Completed	`NCT04360915` - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects	Phase 1